Loading…
Vimta Labs (VIMTALABS)₹504.50−0.44%Healthcare Research, Analytics & Technology
In the Jun 2026 quarter (standalone), Vimta Labs reported sales of ₹109 Cr, up 11.2% from Jun 2025, and net profit of ₹21.02 Cr, up 10.5% year on year. For the year to Mar 2026, sales were ₹408 Cr and net profit ₹78.09 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 64.12 | 73.10 | 73.15 | 75.17 | 85.13 | 90.22 | 94.17 | 98.24 | 102 | 99.23 | 109 | 109 |
| Expenses | 48.01 | 50.07 | 47.07 | 49.03 | 55.03 | 57.08 | 61.03 | 64.09 | 68.09 | 64.06 | 70.09 | 72.05 |
| Operating Profit | 16.95 | 22.92 | 25.90 | 25.91 | 29.90 | 32.92 | 32.87 | 33.90 | 33.89 | 33.88 | 38.88 | 36.86 |
| OPM % | 26.0% | 31.0% | 36.0% | 35.0% | 35.0% | 37.0% | 35.0% | 35.0% | 34.0% | 35.0% | 36.0% | 34.0% |
| Other Income | 0.00 | −0.99 | −0.99 | −0.99 | −0.99 | 4.98 | 1.99 | 1.99 | 2.99 | 0.00 | 2.99 | 3.99 |
| Interest | 1.01 | 1.01 | 1.01 | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 9.03 | 8.03 | 8.04 | 8.04 | 8.03 | 10.04 | 9.03 | 10.04 | 10.04 | 11.05 | 13.04 | 13.04 |
| Profit before tax | 7.99 | 12.98 | 15.96 | 16.97 | 19.95 | 27.97 | 24.94 | 24.98 | 25.94 | 22.97 | 28.96 | 27.97 |
| Tax % | 25.0% | 25.1% | 24.0% | 26.0% | 24.0% | 23.0% | 27.0% | 25.0% | 24.0% | 25.0% | 27.0% | 26.0% |
| Exceptional items | −1.79 | −2.13 | −1.62 | −1.63 | −1.78 | 3.99 | 0.00 | 0.00 | 0.00 | −1.15 | 0.00 | 0.00 |
| Net Profit | 6.01 | 9.01 | 12.01 | 12.03 | 15.01 | 22.02 | 18.02 | 19.03 | 20.03 | 18.04 | 21.03 | 21.02 |
| EPS (Rs) | 1.35 | 2.15 | 2.80 | 2.78 | 3.45 | 4.85 | 4.13 | 4.25 | 4.48 | 3.95 | 4.74 | 4.72 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 138 | 154 | 183 | 213 | 181 | 210 | 276 | 315 | 290 | 345 | 408 | 420 |
| Expenses | 119 | 127 | 138 | 155 | 151 | 156 | 196 | 222 | 195 | 222 | 266 | 274 |
| Operating Profit | 18.93 | 26.94 | 44.88 | 57.81 | 29.93 | 52.81 | 79.80 | 93.65 | 93.65 | 122 | 142 | 144 |
| OPM % | 14.0% | 18.0% | 25.0% | 27.0% | 17.0% | 25.0% | 29.0% | 30.0% | 33.0% | 35.0% | 35.0% | 34.2% |
| Other Income | 0.99 | 0.99 | 0.99 | 1.99 | 2.99 | 0.99 | 0.00 | 2.99 | −3.99 | 4.99 | 6.98 | 9.97 |
| Interest | 1.01 | 2.01 | 5.01 | 5.01 | 4.01 | 2.01 | 2.01 | 3.01 | 2.01 | 2.01 | 1.01 | 0.00 |
| Depreciation | 10.03 | 10.05 | 16.06 | 20.07 | 21.09 | 23.09 | 23.08 | 31.12 | 33.15 | 35.11 | 44.15 | 47.17 |
| Profit before tax | 7.99 | 16.96 | 25.98 | 34.92 | 7.99 | 27.97 | 54.92 | 63.85 | 54.88 | 89.79 | 104 | 106 |
| Tax % | 23.0% | 36.0% | 36.1% | 28.0% | 17.0% | 25.1% | 26.0% | 26.0% | 25.0% | 25.0% | 25.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −1.01 | 0.00 | 0.00 | 0.00 | −1.01 | −1.15 |
| Net Profit | 6.01 | 11.01 | 16.01 | 25.03 | 7.01 | 21.02 | 41.08 | 47.07 | 41.03 | 67.06 | 78.09 | 80.12 |
| EPS (Rs) | 1.46 | 2.41 | 3.73 | 5.74 | 1.58 | 4.82 | 9.30 | 10.70 | 9.28 | 15.15 | 17.39 | 17.89 |
| Dividend payout % | 33.9% | 0.0% | 26.9% | 16.9% | 0.0% | 21.0% | 11.0% | 9.0% | 10.9% | 7.0% | 12.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 8.99 |
| Reserves | 118 | 122 | 132 | 148 | 167 | 169 | 190 | 229 | 276 | 310 | 373 | 447 |
| Borrowings | 4.00 | 25.97 | 43.92 | 39.95 | 25.97 | 31.96 | 30.00 | 18.99 | 14.98 | 18.99 | 8.99 | 3.00 |
| Other Liabilities | 20.89 | 22.88 | 41.79 | 39.80 | 39.81 | 38.81 | 48.77 | 53.74 | 64.68 | 60.70 | 78.62 | 102 |
| Total Liabilities | 146 | 176 | 222 | 231 | 237 | 244 | 273 | 305 | 359 | 393 | 466 | 561 |
| Fixed Assets | 87.78 | 87.79 | 87.65 | 139 | 135 | 131 | 128 | 161 | 167 | 166 | 229 | 304 |
| CWIP | 0.00 | 5.99 | 52.92 | 0.00 | 3.99 | 1.99 | 16.97 | 0.00 | 11.97 | 58.82 | 37.93 | 17.95 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.03 | 6.02 | 6.02 | 6.02 | 0.00 | 0.00 | 2.01 |
| Other Assets | 57.93 | 81.93 | 79.94 | 91.97 | 98.92 | 105 | 122 | 138 | 174 | 170 | 198 | 237 |
| Inventories | 15.96 | 15.96 | 14.96 | 17.94 | 18.95 | 16.96 | 14.97 | 16.96 | 22.93 | 24.95 | 24.92 | 29.94 |
| Trade receivables | 25.98 | 37.98 | 41.99 | 55.98 | 59.02 | 58.04 | 73.03 | 76.97 | 79.98 | 87.04 | 106 | 106 |
| Cash & equivalents | 0.99 | 2.99 | 0.99 | 2.99 | 2.99 | 6.99 | 6.99 | 10.98 | 38.93 | 25.96 | 32.97 | 64.87 |
| Total Assets | 146 | 176 | 222 | 231 | 237 | 244 | 273 | 305 | 359 | 393 | 466 | 561 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 14.99 | −0.99 | 23.96 | 32.97 | 38.94 | 23.97 | 36.95 | 58.93 | 86.88 | 60.91 | 93.87 | 147 |
| Cash from investing activity | −8.01 | −16.01 | −39.03 | −23.99 | −16.01 | −20.01 | −32.03 | −38.04 | −56.99 | −75.99 | −76.03 | −130 |
| Cash from financing activity | −8.98 | 18.96 | 12.95 | −7.97 | −22.94 | −0.99 | −4.99 | −15.96 | −10.97 | −1.99 | −15.94 | −9.97 |
| Net cash flow | −1.01 | 2.01 | −2.01 | 1.01 | 1.01 | 3.01 | 1.01 | 5.01 | 19.02 | −17.02 | 2.01 | 7.01 |
| Capex | 7.98 | 15.95 | 39.91 | 23.95 | 16.95 | 13.97 | 32.94 | 38.87 | 49.83 | 76.78 | 78.85 | 99.74 |
| Free cash flow | 8.01 | −17.03 | −16.03 | 9.02 | 23.05 | 10.03 | 5.01 | 20.03 | 37.07 | −14.03 | 17.04 | 47.09 |
| CFO / OP % | 95.9% | 4.0% | 106.9% | 85.9% | 85.0% | 100.9% | 84.0% | 94.0% | 106.0% | 80.9% | 94.9% | 120.9% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 81 | 99 | 100 | 110 | 99 | 116 | 127 | 101 | 92 | 109 | 112 | 94 |
| Inventory days | 157 | 212 | 182 | 208 | 198 | 190 | 139 | 153 | 194 | 259 | 209 | 202 |
| Days payable | 67 | 78 | 185 | 149 | 116 | 115 | 140 | 109 | 125 | 88 | 89 | 80 |
| Cash conversion cycle | 174 | 236 | 100 | 172 | 184 | 194 | 128 | 147 | 164 | 283 | 235 | 219 |
| Working capital days | 109 | 99 | 22 | 62 | 78 | 64 | 89 | 87 | 78 | 98 | 96 | 83 |
| ROCE % | 6.0% | 7.0% | 11.0% | 17.0% | 20.9% | 6.0% | 14.0% | 24.0% | 24.0% | 20.0% | 24.9% | 25.0% |
For the Jun 2026 quarter, Vimta Labs reported sales of ₹109 Cr, up 11.2% year on year and net profit of ₹21.02 Cr, up 10.5% year on year. The operating margin was 34.0%.
Vimta Labs' sales for the year to Mar 2026 were ₹408 Cr; over the last twelve months they were ₹420 Cr.
Net profit for the year to Mar 2026 was ₹78.09 Cr, and ₹80.12 Cr over the last twelve months. Earnings per share over the same trailing period were ₹17.89.
Vimta Labs reported borrowings of ₹3 Cr at Mar 2026, against cash and equivalents of ₹64.87 Cr.
Cash from operations was ₹147 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹47.09 Cr.